Adaptimmune’s GSK-partnered T cell therapy has shown partial responses in three of the first four myxoid/round cell liposarcoma (MRCLS) patients treated with its Specific Peptide Enhanced Affinity Receptor (SPEAR™) T cells.
Adaptimmune’s NY-ESO T cell therapy targets the NY-ESO cancer antigen present in solid tumors and hematologic cancer types, including synovial sarcoma and multiple myeloma.
Previously in 2015, the company posted positive clinical data of its T cell therapy in treating patients with synovial sarcoma. MRCLS, like synovial sarcoma, is another soft tissue sarcoma but the underlying genetics and clinical manifestations are different in these two tumors.
Of the four patients treated thus far, two patients displayed partial response, one showed unconfirmed partial response and the last one displayed stable disease. The treatment was well-tolerated by all the patients and cytokine release syndrome was managed with standard treatments. Although the size of the dataset is small, the company is hopeful that it’s moving in the right direction and the news has increased its shares to nearly 20%.
GSK owns the exclusive license to research, develop and commercialize the NY-ESO SPEAR T-cell therapy program. The therapy is currently being investigated for a range of cancers, including: sarcoma, non-small cell lung cancer, and ovarian cancer. The therapy is also being investigated in combination with Merck’s Keytruda (pembrolizumab), an anti-PD-1 inhibitor.
Rafael Amado, Adaptimmune’s CMO commented: “We are encouraged by the initial responses seen in the first patients with MRCLS treated with NY-ESO SPEAR T-cells, as it validates the potential of our platform to treat a broad range of tumors, including those that are known to be unresponsive to current immunotherapies”.
Source: Adaptimmune Announces Responses in Second Solid Tumor Indication with NY-ESO SPEAR T-cells, March 2018. Press Release